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ABSTRACT
Immune checkpoint inhibitors have emerged as a mainstay
of melanoma therapy and are playing an increasingly impor-
tant role in the treatment of other tumor types. The clinical
benefit affordedby these treatments canbeaccompanied by a
unique spectrum of adverse events, called immune-related
adverse events (irAEs),which reflect thedrug’s immune-based
mechanism of action. IrAEs typically originate in the skin,
gastrointestinal tract, liver, and endocrine system, although
other organ systemsmay also be affected.This article provides
an overview of irAEs associatedwith anti-programmed death-1
(anti-PD-1) antibodies (nivolumab and pembrolizumab)
as monotherapy or in combination with anti-cytotoxic
T-lymphocyte antigen-4 inhibition (ipilimumab), followed
by a discussion of irAEs of special clinical interest based on the
potential for morbidity, frequent steroid use, and inpatient
admission.We review clinical trial data and provide recommen-
dations on how to manage irAEs associated with anti-PD-1
agents based on clinical experience and established man-
agement guidelines. We further illustrate the practical con-
siderations of managing irAEs by presenting three cases of
immune-related toxicity in melanoma patients treated with
nivolumab or pembrolizumab. A better understanding of
the identification and management of irAEs will help inform
health careproviders about the risks associatedwith anti-PD-1
treatment, to ensure the safe and appropriate use of these
important new treatments.TheOncologist 2016;21:1230–1240
Implications forPractice: Immunecheckpoint inhibitorshavedemonstratedsignificant clinical benefit inadvancedmelanomaand
other tumor types.These treatments areassociatedwith immune-relatedadverseevents (irAEs),whichmost commonly affect the
skin and gastrointestinal tract, and, to a lesser extent, the liver, endocrine system, and other organs. This review focuses on the
management of irAEs after treatment with anti-programmed death-1 (anti-PD-1) antibodies (nivolumab or pembrolizumab) as
monotherapy or in combination with anti-cytotoxic T-lymphocyte antigen-4 inhibition (ipilimumab) in patients with advanced
melanoma.Abetterunderstandingof themanagementof irAEswill helpensure the safeandappropriateuseof anti-PD-1agents in
melanoma and other tumor types.
INTRODUCTION
Antibodies that target key immune checkpoints, such as
cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed
death-1 (PD-1), have emerged as clinically effective treatment
options for melanoma and other tumor types, including non-
small-cell lung cancer and renal cell carcinoma. Ipilimumab, a
fullyhuman IgG1monoclonal antibodyagainstCTLA-4,was the
first therapy to demonstrate an overall survival (OS) benefit
in a randomized, controlled, phase 3 study of patients with
advanced melanoma [1] and the first immune checkpoint
inhibitor to be approved by the Food and Drug Administra-
tion (FDA). In 2014, the anti-PD-1 antibodies nivolumab and
pembrolizumab were added to the list of FDA-approved
agents for advanced melanoma and have shown benefit in
randomized phase 3 studies. Nivolumab demonstrated
improved OS versus dacarbazine in patients with BRAF wild-
type, previously untreated, advanced melanoma (phase 3
study CheckMate 066) [2] and a higherobjective response rate
(ORR) than chemotherapy in patients who had progressed
after ipilimumab, or ipilimumab and a BRAF inhibitor if BRAF
mutation-positive (phase 3 study CheckMate 037) [3].
Pembrolizumab prolonged progression-free survival (PFS)
and improved OS versus ipilimumab alone in patients with
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advanced melanoma (phase 3 study KEYNOTE-006) [4]. In
October 2015, the combination of nivolumab plus ipilimumab
was added to the treatment armamentarium for advanced
melanoma in the U.S. based on improved ORR and PFS
versus ipilimumab in previously untreated patients with
BRAF wild-type melanoma (randomized phase 2 study
CheckMate 069) [5]. In January 2016, the FDA expanded
the indication for nivolumab plus ipilimumab to include pa-
tients with BRAF-mutated melanoma based on improved
PFS versus ipilimumab alone in previously untreated patients
(phase 3 study CheckMate 067, which included patients with
BRAF wild-type melanoma and those with BRAF-mutated
melanoma) [6].
Given the availability of anti-PD-1 agents as treatment
options for advanced melanoma, non-small-cell lung cancer,
and renal cell carcinoma and the role they are expected to
play in other tumor types, it is important to educate health
care providers on the safe and appropriate use of these
important new treatments to ensure maximum clinical ben-
efit for patients. This article provides a general overview of
the safety profile of immune checkpoint inhibitors, followed
by a more detailed discussion of adverse events (AEs) of
special clinical interest. We provide recommendations on
how to manage AEs associated with anti-PD-1 agents based
on established treatment guidelines and our clinical expe-
rience, illustrated by three case studies of patients with
advanced melanoma.
GENERAL SAFETY PROFILE ASSOCIATED WITH IMMUNE
CHECKPOINT INHIBITORS
Immune-related adverse events (irAEs) reflect the immune-
basedmechanism of action of checkpoint inhibitors.Themost
common irAEs associated with immune checkpoint inhibi-
tion affect the skin and gastrointestinal (GI) tract, although
the liver, endocrine system, and other organs may also be af-
fected to a lesser extent [7–9]. The rates of high-grade (grade
3/4 for nivolumab alone, ipilimumab alone, or nivolumab plus
ipilimumab combination; grades 3–5 for pembrolizumab)
treatment-related AEs associated with anti-PD-1 agents are
generally lower than those observed with anti-CTLA-4 treat-
ment, with a similar incidence reported with nivolumab and
pembrolizumab treatment (Table 1) [4, 6]. The rates of high-
grade, treatment-related AEs are higher when anti-PD-1
antibodies are combined with anti-CTLA-4 treatment, com-
paredwith anti-PD-1 or anti-CTLA-4monotherapy (Table 1) [4,
6]. Similar rates of treatment-related grade 3/4 AEs with anti-
PD-1 therapy have been reported across tumor types (Table 2)
[2, 3, 10–13]. The majority of grade 3/4 irAEs occur during the
first 12–14weeks of treatment,with characteristic timing [14].
In the nivolumab plus ipilimumab combination arm of the
randomizedphase2studyCheckMate069, skin irAEsappeared
with a median time of onset within the first ∼2 weeks of
treatment, followed by GI irAEs at ∼7 weeks, and endocrine
and hepatic events between ∼9 and 12 weeks, respectively
[14]. The majority (∼80%) of these events, with the exception
ofendocrinopathies, resolvedwithinamedianof5weeks from
onset with the use of immune-modulating medication [14]. In
the following sections, we discuss irAEs of special clinical
interest based on the potential for morbidity, frequent steroid
use, and inpatient admission.
GASTROINTESTINAL IRAES
GI irAEs are of particular interest to the medical community
because they are associated with a high incidence of treatment-
related grade 3/4AEs relative to other organ systems (Table 1) and
may lead to inpatient admission due to diarrhea, obstruction,
perforation, or toxic megacolon. GI irAEs that are commonly
reported with anti-PD-1 treatment include colitis, diarrhea, and
enteritis. Gastritis or esophagitis has also been seen. According to
the National Cancer Institute Common Terminology Criteria for
Adverse Events (CTCAE; version 4.03), colitis refers to abdominal
pain, bloody stools, or peritoneal signs, whereas diarrhea is based
onstool frequencyalone[15].Enteritis isassociatedwithsymptoms
similar to colitis, but the inflammation involves the small bowel.
Althoughthese termsareseparately recorded inclinical trialsasper
CTCAE, clinically, they present along a similar spectrum. In the
phase 3 studies CheckMate 067 and KEYNOTE-006, the incidence
of high-grade colitis and diarrhea combined was 2.8% with
nivolumab alone, 2.9% with pembrolizumab alone, and ∼17%
with the nivolumab plus ipilimumab combination (Table 1) [4, 6].
Guidelines are available on how to appropriately manage
GI AEs associated with immune checkpoint inhibitors (Fig. 1A).
Close monitoring and prompt treatment of early symptoms can
reduce the risk of more severe toxicity, such as GI perforation.
Noninflammatory causes of symptoms, such as infection with
Clostridium difficile or other pathogens, should be ruled out.
Colonoscopy and biopsy should be considered if the diagnosis is
unclear or in the case of chronic grade 2 AEs (4–6 stools per day
overbaseline,abdominalpain,bloodinstool).Mostcasesrespond
to treatment with systemic corticosteroids; loperamide can also
be helpful. Patients should be closelymonitored and encouraged
to report worsening symptoms immediately. Systemic corticoste-
roids are required in the case of grade 3/4 AEs ($7 stools per day
over baseline, incontinence, severe abdominal pain, and life-
threatening perforation) and should be strongly considered if
grade2AEspersist inspiteofsupportivecare.Oralsteroidsstarting
at 1–2mg/kg per day of prednisone can be used, but for patients
requiringhospitalization,whoarenilperos (nothingbymouth),or
who have significant comorbidities, intravenous methylprednis-
olone should be used for 1–2 days before beginning an oral taper
of prednisone.Waxing andwaning of symptoms is common, and
several courses of systemic corticosteroids over no less than 30
days may be required. If symptoms improve with steroid treat-
ment, steroids should be continued until grade 1 or 0 toxicity is
reached, followed by a taper over at least 30 days. In steroid-
refractory cases, after 72 hours, the tumor necrosis factor-a
(TNF-a) blockingagent infliximab (5mg/kg onceevery 2weeks)
may be used, but not in patients with GI perforation or sepsis.
Treatmentwith infliximabcandramatically improveGIAEs,with
occasional alleviation of symptoms within 24 hours.
Treatment with infliximab can dramatically improve
GI AEs, with occasional alleviation of symptoms within
24 hours.
ENDOCRINE IRAES
Endocrine irAEs are also seen following treatment with
immune checkpoint inhibitors, and are generally of grade 1
www.TheOncologist.com ©AlphaMed Press 2016
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and 2, but they are of special clinical interest because they
can be difficult to diagnose. Nonspecific complaints, such as
fatigue, nausea, amenorrhea, erectile dysfunction, hypoten-
sion, hyponatremia, hypoglycemia, and eosinophilia may re-
flect endocrine dysfunction. Low rates (,1%) of high-grade
hypothyroidism or hypophysitis were reported in CheckMate
067 and KEYNOTE-006 (Table 1) [4, 6].
Guidelines are available on how to appropriately man-
age endocrine AEs following immune checkpoint inhibition
(Fig. 1B). Laboratory testing for adrenocorticotropic hormone
(ACTH), cortisol, T4, thyroid-stimulating hormone, and testos-
terone in males, may help identify endocrine dysfunction. If
hypophysitis is suspected, especially with a headache or vi-
sual symptoms, consider a magnetic resonance imaging (MRI)
scan of the brain with pituitary cuts and visual field testing.
Treatment with immune checkpoint inhibition may continue
with low-gradeendocrine toxicity, althoughpatients shouldbe
closelymonitored. If adrenal crisis is suspectedbased on severe
Table 2. Incidence of treatment-related AEs of interest in major trials of nivolumabmonotherapy in melanoma, lung cancer, and
renal cell carcinoma
Event
Patients reporting event, %
Melanomaa Lunga RCCb
CheckMate 037 CheckMate 066 CheckMate 017 CheckMate 057 CheckMate 153b CA209-010
Any
grade
Grade
3/4
Any
grade
Grade
3/4
Any
grade
Grade
3/4
Any
grade
Grade
3/4
Any
grade
Grade
3/4
Any
grade
Grade
3/4
Pruritus 16.0 0 17.0 0.5 2 0 8 0 NR 9 2
Rash 9.3 0.4 15.0 0.5 4 0 9 ,1 1.9 0 7 0
Diarrhea 11.2 0.4 16.0 1.0 8 0 8 1 6.5 0.3 11 0
Colitis 1.1 0.7 1.0 0.5 1 1 NR NR NR
Elevated ALT 2.6 0.7 1.5 1.0 2 0 3 0 NR 4 2
Elevated AST 4.1 0.4 1.0 0.5 2 0 3 ,1 NR 7 2
Hypothyroidism 5.6 0 4.4 0 4 0 7 0 3.8 0.1 7 2
Hypophysitis NR 0.5 0.5 NR NR NR NR
Pneumonitis 1.9 0 1.5 0 5 1 3 1 0.8 0.3 4 0
Patientswere treatedwithNIVO3mg/kg in themelanomaand lungcancerstudies.Patients receivedNIVO0.3,2,or10mg/kg in theRCCstudyCA209-010;
only data from the NIVO 2 mg/kg group are reported.
aAEs of potential immunological etiology.
bBased on patients with an Eastern Cooperative Oncology Group performance status of 0 or 1.
Abbreviations: AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NIVO, nivolumab; NR, not reported; RCC, renal cell
carcinoma.
Table 1. Incidence of treatment-related AEs of interest associated with immune checkpoint inhibitors
AE
Patients reporting event, %
NIVOa,b NIVO1 IPIa,c IPIa,d Pembroe,f
Any grade Grade 3/4 Any grade Grade 3/4 Any grade Grade 3/4 Any grade Grade 3-5
Pruritus 18.8 0 33.2 1.9 35.4 0.3 14.1 0
Rash 25.9 0.6 40.3 4.8 32.8 1.9 13.4 0
Diarrhea 19.2 2.2 44.1 9.3 33.1 6.1 14.4 1.1
Colitis 1.3 0.6 11.8 7.7 11.6 8.7 2.9 1.8
Elevated ALT 3.8 1.3 17.6 8.3 3.9 1.6 1.4 0.4
Elevated AST 3.8 1.0 15.3 6.1 3.5 0.6 2.2 0.4
Hypothyroidism 8.6 0 15.0 0.3 4.2 0 7.6 0
Hypophysitis 0 0 0.3 0 0 0 0.4 0.4
Pneumonitis 1.3 0.3 6.4 1.0 1.6 0.3 1.8g 0.4g
aBasedondata fromthephase3 studyCheckMate067 [6]. Incidenceofhypophysitis andpneumonitis is basedonunpublisheddata fromCheckMate067.
bOne treatment-related death (neutropenia) was reported.
cNo treatment-related deaths were reported.
dOne treatment-related death (cardiac arrest) was reported.
eBased on data from the phase 3 study KEYNOTE-006 every 3 week dosing group [4].
fNo treatment-related deaths were reported.
gAE of special interest, regardless of attribution of study drug.
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; IPI, ipilimumab; NIVO, nivolumab; Pembro,
pembrolizumab.
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dehydration, hypotension, and/or shock out of proportion to
the current illness, administer stress-dose steroids in an in-
patient setting, delay or discontinue treatment with anti-PD-1
therapy, and consider hormone-replacement therapy. Hypo-
thyroidism can also be preceded by the signs and symptoms of
hyperthyroidism over a period of days to weeks, which mimics
the clinical presentation of Hashimoto’s thyroiditis.
HEPATIC IRAES
Hepatotoxicity can be observed following treatment with
immune checkpoint inhibition and usually presents as an
asymptomatic increase in alanine aminotransferase (ALT),
aspartate aminotransferase (AST), and/or total bilirubin. In
phase 3 studies CheckMate 067 and KEYNOTE-006, the
incidence of high-grade ALT and AST combined was 2.3%with
nivolumab alone, 0.8%with pembrolizumab alone, and 14.4%
with nivolumab plus ipilimumab combination (Table 1) [4, 6].
Guidelines are available on how to appropriately manage
hepatic AEs following immune checkpoint inhibition (Fig. 1C).
One should perform a standard workup to ensure that
elevations in liver function tests (LFTs) are not because of
noninflammatory causes, such as progressive liver disease,
viralhepatitis, sepsis, orconcurrentmedications. Liver imaging
tests and biopsy should be considered, and in some cases
biopsies have revealed diffuse lymphocytic infiltrates consis-
tent with immune-related hepatitis. For grade 2 hepatic AEs
(ALTor AST. 3.0 to#53 upper limit of normal [ULN] and/or
total bilirubin . 1.5 to # 3 3 ULN), delay treatment and
increase the frequency ofmonitoring to every 2–3 days. If LFTs
return to baseline, resume treatment and routinemonitoring.
If elevations in LFTs persist for .5–7 days or if they worsen,
administer intravenous methylprednisolone at a dose of
0.5–1.0 mg/kg per day. Steroids may be tapered over at least
30 days when LFTs return to grade 1 or baseline, and then
treatment with anti-PD-1 therapy may resume. For grade 3/4
hepaticAEs (ALTorAST.5.03ULNand/ortotalbilirubin.33
ULN), discontinue treatment, increase the frequency of mon-
itoring to every 1–2 days, and administer intravenous methyl-
prednisolone at a dose of 1.0–2.0 mg/kg per day. Steroids
should be tapered over at least 30 days if elevations in LFTs
return to grade 2. If LFT elevations donot respond to steroids,
administer mycophenolate mofetil orally 1 g twice daily.
Infliximab should not be used in this setting because it can
cause hepatotoxicity.
Figure 1. Management algorithms for GI (A), endocrine (B), hepatic (C), and pulmonary (D) irAEs.
Abbreviations:ADL, activitiesofdaily living;ALT, alanineaminotransferase;AST, aspartateaminotransferase; b.i.d., twicedaily; CTCAE,
Common Terminology Criteria for Adverse Events; fT4, free T4; G3, grade 3; GI, gastrointestinal; ID, infectious disease; I-O, immuno-
oncology; IVIG, i.v. immunoglobulin; LFT, liver function test; LLN, lower limit of normal; MRI, magnetic resonance imaging; NCI, National
Cancer Institute; p.o., orally; T. bili, total bilirubin; TSH, thyroid-stimulating hormone; ULN, upper limit of normal; v4, version 4.
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OTHER AES
Immune-Related Pneumonitis
Immune-related pneumonitis is a serious AE, particularly in
patients with lung cancer who may have poor lung function
because of prior smoking [16]. In an early dose-finding study
(CA209-003) that evaluated nivolumab monotherapy across
multiple tumor types, three treatment-related deaths (1%)
due to pneumonitis were reported (two patients with non-
small-cell lung cancer and one patient with colorectal cancer)
[17]. The rate of grade 3/4 pneumonitis associated with
nivolumab treatment was#1% in phase 3 non-small-cell lung
cancer studies CheckMate 017, CheckMate 057, and Check-
Mate 153, with no deaths reported due to pneumonitis
[10–12]. In the phase 3melanoma studies CheckMate 067 and
KEYNOTE-006, high-grade, immune-related pneumonitis was
reported in#1% of patients [4, 6], and no deaths were due to
pneumonitis. In contrast, symptomatic pneumonitis is quite
rare with ipilimumab, and diffuse, grade 3/4 pulmonary
toxicity isoneof the irAEsthatdistinguishesanti-PD-1andanti-
CTLA-4 immune checkpoint inhibitors.
Guidelines are available on how to appropriately man-
age pulmonary immune-related AEs, including pneumoni-
tis, following treatment with immune checkpoint inhibitors
(Fig. 1D). Bronchoscopy and lung biopsy should be considered
for patients with changes in respiratory status, including
symptoms of upper respiratory infection, cough, shortness of
breath, or decrease in pulse oximetry below 90% on exertion.
For patients with grade 2 mild-to-moderate symptoms or
worsening of symptoms from baseline, withhold treatment,
monitor the patient daily, and administer corticosteroids
(1.0 mg/kg per day intravenous methylprednisolone). If upon
reassessment (every1–3days) symptoms improve tobaseline,
taper oral steroids starting at 1 to 2 mg/kg per day of
prednisone over at least 30 days before resuming treatment. If
no improvement in symptoms is observed after 2 weeks or if
symptomsworsen,treatas recommended forgrade3/4 severe
events. In severe cases (grade 3/4 symptoms with new or
worseninghypoxia or life-threatening symptoms), discontinue
treatment, hospitalize the patient with daily monitoring, and
administer corticosteroids (2–4 mg/kg per day of intravenous
methylprednisolone). If symptoms improve to baseline,
patients can take oral steroids, which should be tapered over
aperiodofat least6weeks. If symptomspersistorworsenafter
2 days, consider the addition of noncorticosteroid immuno-
suppressive medication, such as infliximab or mycophenolate
mofetil.
Immune-Related Pancreatitis
Immune-relatedpancreatitis hasbeenreported in less than1%
of patients treated with nivolumab or pembrolizumab [8, 9].
Symptoms resembleclassic pancreatitiswithupperabdominal
Figure 1. Continued.
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or back pain. Often radiographic findings such as stranding
of the pancreas are not present, but amylase and lipase can
be elevated. Although the routine evaluation of amylase
and lipase levels in asymptomatic patients is not recom-
mended outside of a clinical trial, symptomatic patients
should have their amylase and lipase levels drawn for
diagnostic clarification [18]. Treatment of immune-related
pancreatitis is based on the severity of symptoms. High-
dose corticosteroids starting at 1–2 mg/kg per day of
prednisone are recommended in patients with at least mod-
erate symptoms.
CASE STUDIES
In this section, we present three case studies that illustrate
unique clinical scenarios and the practical management of
irAEs that have occurred following treatment with nivolumab
or pembrolizumab. The first case study focuses on a patient
with metastatic melanoma who received nivolumab after
ipilimumab-induced colitis. The second case study focuses
on a patient with metastatic melanoma who had pituitary
dysfunction following pembrolizumab treatment. The third
case study is a patient with stage IV melanoma who expe-
rienced immune-related hepatitis following pembrolizumab
treatment.
Case History 1
The patient is a 59-year-old man originally diagnosed with
superficial spreading melanoma (BRAF V600E/K mutation-
negative) from his right posterior shoulder in July 2013 treat-
ed with wide excision. He developed a local recurrence in
February 2014, and on a subsequent restaging positron
emission tomography (PET)-computed tomography (CT),
new pulmonary nodules were noted, which were biopsy-
proven to be melanoma. Brain MRI was negative for me-
tastasis. Following extensive discussions regarding options,
he was treated with ipilimumab from May 2014 to July
2014 (four doses in total). Treatment was complicated
by enterocolitis manifested by bloating, mild abdominal
pain, and four to five watery stools per day above baseline.
CT enterography failed to identify signs of colitis, and
infectious workup was negative. He was managed with
supportive care and prednisone at a dose of 1 mg/kg
by mouth daily. Because of only modest improvement in
symptoms, he was hospitalized and given high-dose in-
travenous (i.v.) steroids and, later, infliximab two times due
to refractory colitis. Despite thenegative CTenterography, a
colonoscopy was performed and demonstrated extensive
mucosal ulcerations throughout the large bowel consistent
with severe pancolitis (Fig. 2A, 2B). The patient steadily
Figure 1. Continued.
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improved, and prednisone was tapered over 8 weeks with
no recurrent symptoms.
Initial surveillance imaging after treatment revealed
a mixed response. Repeat colonoscopy in October 2014
revealed significantly improved, but persistent,mild colitis.
Because of symptomatic progression of disease on his
back and right axilla, he underwent palliative resection in
November 2014. Subsequent repeat imaging revealed two
new brain lesions, which were treated with stereotactic
radiosurgery.
Repeat colonoscopy in March 2015 revealed patchy mild
inflammation with few scattered ulcerations and mild
persistent colitis on biopsy (Fig. 2C, 2D). Because of the
need for additional systemic therapy, it was decided to start
mesalamine 800 mg twice daily and proceed with nivolumab
at 3 mg/kg i.v. every 2 weeks despite the mild residual colitis.
After six cycles of nivolumab, repeat imaging demonstrated
an excellent partial response and no recurrence of GI symp-
toms. The patient continued on nivolumab and mesalamine.
No repeat colonoscopy has been performed because of the
absence of symptoms.
Persistence of symptoms .3 days despite high-dose
steroids warrants the consideration of infliximab. Symptoms
typically resolve within one to three doses and allow the
safe and steady tapering of steroids over time. The safety of
anti-PD-1 therapy after resolution or significant improvement
in colitis from prior anti-CTLA-4 treatment is unknown. Given
themechanismofactionand lower riskofcolitiswithanti-PD-1
compared with anti-CTLA-4 treatment, agents such as nivolumab
may be acceptable treatments after a prior anti-CTLA-4-related
side effect such as colitis. This approach needs further study
in prospective clinical trials.The effectiveness of anti-inflammatory
bowel medications such as mesalamine is unknown, but is also
worthy of investigation.
Case History 2
A 59-year-old man with a history of significant depression and
stage IIIB cutaneous melanoma underwent a routine surveil-
lancePETscan inDecember2014, showingsuspicious lesions in
his liver and spleen. Biopsy of a liver lesion confirmed NRAS
mutant, metastatic melanoma. In October 2014, he began
treatment with ipilimumab 3 mg/kg, and he tolerated four
doses with only mild pruritus. He continued to feel well, but a
PET scan in February 2014 showed progressive disease with
increasing size of his hepatic lesions and new subcutaneous
lesions. He additionally became more fatigued, which he
attributed to becoming particularly depressed by his mela-
noma progression.
In March 2015, he began treatment with pembrolizumab
2 mg/kg scheduled every 3 weeks. Two weeks after his first
Figure 1. Continued.
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infusion with pembrolizumab, he began complaining of
even more significantly worsening depression, fatigue, and
anxiety.Hevisitedhispsychiatrist,whoadjustedhis psychiatric
medications, but his symptoms did not improve. A brain MRI
was unremarkable for metastatic disease, and his pituitary
appeared normal in size. Basic laboratories including electro-
lytes and blood counts were normal. Thyroid function testing
was normal. Amorning cortisol, however, was found to be low
at 0.8 mg/dL (lower limit of normal: 5 mg/dL), and ACTH was
undetectable. He was diagnosed with secondary adrenal
insufficiency, likely due to pituitary dysfunction. After starting
treatment with replacement doses of hydrocortisone (20 mg
each morning and 10 mg each evening, both by mouth), his
energy and depressive symptoms immediately improved.
Although his second pembrolizumab dose was delayed, he
ultimately resumed pembrolizumab, which has resulted in
stabilization of his melanoma—now ongoing for approxi-
mately 8 months.
This case illustrates the importance of always considering
the possibility of pituitary dysfunction when patients re-
ceiving immunotherapy present with fatigue, even though
other explanations, such as depression, may seem likely. The
rate of pituitary dysfunction with anti-PD-1 agents has been
reported,10% in clinical trials [19], but because of variabil-
ity in assessment as per protocol requirements, the clinical
incidence is suspected to be higher. “Fatigue” is one of the
most commonly reported symptoms with anti-PD-1 treat-
ment [2, 4]. Although fatigue may be related to many causes
such as the underlying cancer and possibly depression, as in
our patient’s case, we suggest considering pituitary dysfunc-
tion in any patient with this complaint; a correct diagnosis
can lead to appropriate treatment and symptomatic relief.
Typically, endocrinopathy due to anti-PD-1 agents appears
at a median time of ∼10 weeks after treatment initiation
[20]. It is possible our patient’s endocrinopathy arose from
prior ipilimumab, exacerbated by the more recent initiation
of pembrolizumab. After achieving successful symptom
relief on stable doses of replacement steroid, we reinitiated
pembrolizumab treatment. This demonstrates that patients
with this side effect do not need to permanently discontinue
anti-PD-1 therapy, particularly early in a treatment course,
while experiencing clinical benefit andwhenonstablehormone
doses.
Case History 3
A 48-year-old female was initially diagnosed with stage IIB
melanoma of the right gluteal area in March 2007 and was
treated with wide excision and right inguinal sentinel lymph
node biopsy. In September 2012, the patient was diagnosed
with stage IV melanoma with multiple lung metastases, a
Figure 2. Colonoscopy and histopathology results for case history 1. (A): Colonoscopy in August 2014. Discontinuous areas of small and
large, deeply cratered ulceratedmucosa are seen throughout entire colon.Mucosa diffusely erythematouswith altered vascular pattern,
edematous and friable (black arrow). (B): Histopathology (hematoxylin and eosin stain) of right-sided colon (3200). Lamina propria
lymphoplasmacytosis and intensely regenerative epithelium (black arrow). Deep crypts contain apoptotic debris (white arrow). (C):
Colonoscopy in March 2015. Patchy mild inflammation characterized by pseudopolyps, aphthous ulcers (black arrow), and shallow
ulcerations scattered throughout colon. (D): Histopathology (hematoxylin and eosin stain) of cecum (3200) in March 2015. Mild
architectural distortion and laminapropria chronic inflammation (similar toquiescent ulcerative colitis). Basal lymphoid aggregate is seen
in deep mucosa and submucosa (black arrow).
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left axillary lymph node metastasis, and a subcutaneous
metastasis of the right abdominal wall, with evidence of
BRAF V600E mutation in one of these lesions. Treatment
with vemurafenib 960 mg twice daily was initiated, and 4
months later the patient progressed. The patient was then
treated with four cycles of ipilimumab 3 mg/kg, but again
progressed.
After an initial examination at the Skin Cancer Unit at the
University Hospital Essen, the patient was enrolled in the
phase 2 study KEYNOTE-002 (pembrolizumab 2 mg/kg
versus 10 mg/kg) and received her first dose of study drug
in May 2013. One week later, the patient experienced
coughing, stinging eyes, transient elevation of g-glutamyl
transpeptidase (g-GT) (grade 3), total bilirubin (grade 2),
and glutamic oxaloacetic transaminase/glutamic pyruvic
transaminase (GOT/GPT) (grade 1). C-reactive protein (CRP)
was 31 mg/dL (normal ,0.5 mg/dL). Hepatitis serology
and liver autoantibodies were normal. LFT results and CRP
levels were noted to be spontaneously decreasing. A CT
scan of the thorax/abdomen showed no evidence of pneu-
monitis and normal hepatic parenchyma. There was no
evidence of melanoma progression. At a follow-up appoint-
ment, ∼3 weeks after the patient received a single dose of
pembrolizumab, shehad recurrent ocular pain, redness, and
photophobia. Ophthalmological examination revealed ev-
idence of iritis, and laboratory tests revealed the following:
total bilirubin, 3.8mg/dL (,1.2); GOT, 1,557U/L (,35); GPT,
1,122 U/L (,35); alkaline phosphatase, 628 U/L (,100);
g-GT, 313 U/L (,35); glutamate dehydrogenase, 57.9 U/L
(,5); and CRP, 4.8 mg/dL (,0.5). These AEs were classified
as immune-related hepatitis and iritis, and the patient was
admitted to the hospital. An ultrasound-guided liver biopsy
showed (peri-) portal and lobular hepatitis with abun-
dant eosinophils (Fig. 3A, 3B). Treatment with prednisolone
2 mg/kg and mycophenolate mofetil 1 g daily was initiated.
The patient received eye drops to treat the mydriasis and
dexamethasone eye drops for inflammation. She was mon-
itoreddaily, andwithin 7days, transaminase levels decreased
by half.
The onset of immune-related hepatitis and iritis coin-
cided with a clinical response (Fig. 3C, 3D). Radiological
evidence from a CT scan of the thorax/abdomen confirmed
that the patient had a partial response according to RECIST
v1.1. In October 2013, the patient experienced symmet-
rical leucotrichia, which started on the face and subse-
quently extended to the hair on the entire body. Tumor-marker
and liver serology tests showed that total bilirubin, S-100,
GPT, and lactate dehydrogenase levels continued to drop.
In November 2013, the patient continued to have a partial
response in target lesions; however, there was evidence
of new metastases (subcutaneous and pulmonary), and
the patient was removed from the KEYNOTE-002 study.
In December 2013, reinduction with ipilimumab 3 mg/kg
was recommended, and after four cycles, there was no
recurrence of irAEs, and LFTs were normal. As of February
2014, the lung metastases were stable, but tumor burden
in the right groin was growing. Complete lymph node dis-
section of the right groin was performed in March 2014,
and as of January 2016, the patient is still alive and in good
condition.
Figure 3. Images for case history 3. (A, B): Liver biopsy pathology of (peri-) portal and lobular hepatitis with abundant eosinophils (white
arrows) captured at 3200 and 3400, respectively. (C, D): The patient experienced a partial response following a single dose of
pembrolizumab treatment.
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This case illustrates that treatment of melanoma with an
anti-PD-1 agent requires good communication between
patients and providers, as well as close clinical and serological
monitoring. Despite the more common development of irAEs
after several cycles of therapy, irAEs can occur early in the
course of treatment, and early recognition and treatment
according to established management guidelines is critical. A
single dose of pembrolizumab can lead to rapid, long-lasting
remission of melanoma metastases, which is maintained
during irAE management despite the use of immunosup-
pressive therapy.
SUMMARY
Recommendations for treating irAEs come from general
clinical consensus and experience because no prospective
trials have been conducted to test whether one manage-
ment strategy is superior to another. Early recognition and
treatment are believed to be important in mitigating the
severity of irAEs. Because irAEs likely arise from general and
organ-specific alterations in immunologic reactivity, immuno-
suppression for relatively brief periods of 2weeks to 2months
is often necessary. Prolonged immunosuppression greater
than 28 days may predispose patients to opportunistic
infections, and prophylaxis against infectious organisms
may be appropriate, as per National Comprehensive Cancer
Network guidelines.The important lessons to be learned from
managing irAEs with nivolumab and pembrolizumab include
the need for good communication between providers and
patients, the need to recognize and treat high-grade irAEs
early, and the need to administer prolonged steroid tapers of
not less than 30 days durationwhen treating high-grade irAEs.
It is recommended that steroids be completely tapered, or
replacement corticosteroids be started in the case of an
endocrinopathy, before considering reinstituting treatment
with a PD-1 antibody if an irAE was not felt to be dose limit-
ing. General guidelines for the management of irAEs are
provided in Figure 1. In addition, a general approach to toxicity
management of irAEs is provided by the Food and Drug
Administration Risk Evaluation and Management Strategies
[21], which was designed for ipilimumab, but is also ap-
plicable tonivolumabandpembrolizumab. Persistent grade2
irAEs more than 5–7 days should be treated as if they were a
high-grade irAE, and initial treatmentwith i.v. steroids for the
first 1 or 2 days is appropriate for patients who require
hospitalization or who are felt to have significant comorbid-
ities. Lack of resolution of symptoms of colitis and possibly
other high-grade irAEs within 72 hours may require use of
the i.v. TNF blocking antibody infliximab, except for cases of
hepatotoxicity. Dose reductions of PD-1 antibodies and/or
ipilimumab have not been utilized in any trial of those agents
and are not recommended after resolution of toxicity. A
better understanding of the identification and management of
irAEswill help ensure the safe and appropriate use of anti-PD-1
agents.
Early recognition and treatment are believed to be
important in mitigating the severity of irAEs. Because
irAEs likely arise from general and organ-specific
alterations in immunologic reactivity, immunosup-
pression for relatively brief periods of 2 weeks to 2
months is often necessary.
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Implications for Practice:
Immune checkpoint inhibitors are already part of oncologists’ therapeutic arsenal as effective therapies for otherwise
untreatable neoplasias, such asmetastatic melanoma or lung cancer.Their use is expected to increase exponentially in the
near future as additional agents become available and their approval is extended to different tumor types. Adverse events
affecting the endocrine systemareamong themost frequent and complex toxicities oncologistsmay face, and somemaybe
life-threatening if not recognized. This study reviews endocrinopathies associated to immune checkpoint inhibitors
available to date. Incidence, timing patterns, and clinical presentation are discussed, and practical recommendations for
management are proposed.
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